The Influence of Cytomegalovirus Infection, Confirmed by pp65 Antigen Presence, on the Development of Cardiac Allograft Vasculopathy

Transplantation Proceedings

Volumn 39, Issue 9, 2007, Pages 2866-2869

  Zakliczynski M ^a   Krynicka Mazurek, A ^b   Pyka, L ^a   Trybunia, D ^a   Nadziakiewicz, P ^a   Przybylski, R ^a   Zembala, M ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b The First Department of Internal Medicine   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65;

ADULT; ANGIOCARDIOGRAPHY; ANTIGEN DETECTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CORONARY ARTERY OBSTRUCTION; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS DETECTION;

ADULT; CORONARY DISEASE; CORONARY VESSELS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS;

EID: 36048942096     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.09.013     Document Type: Article

References (12)

1. Registry of the International Society for Heart and Lung Transplantation. Twenty-second official adult heart transplant report: 2005. J Heart Lung Transplant 24 (2005) 945
2. Mehra M.R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 6 (2006) 1248
3. Egan J.J., Barber L., Lomax J., et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thoax 50 (1995) 9
4. Sharples L.D., Caine N., Mullins P., et al. Risk factor analysis for the major hazards following heart transplantation-rejection, infection, and coronary occlusive disease. Transplantation 52 (1991) 244
5. Fateh-Moghadam S., Bocksch W., Wessely R., et al. Cytomagalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 76 (2003) 1470
6. Petrakopoulou P., Kübrich M., Pehlivanli S., et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 110 suppl II (2004) II-207
7. Potena L., Holweg C., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalvirus infection. Transplantation 82 3 (2006) 398
8. Valantine H. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 (2003) 169
9. Srivastava R., Curtis M., Hendrickson S., et al. Strain specific effects of cytomegalovirus on endothelial cells: implications for investigating the relationship between CMV and cardiac allograft vasculopathy. Transplantation 68 (1999) 1568
10. Valantine H. Prevention of cardiac allograft vasculopathy with Certican(everolimus): Stanford University Experience within the Certican phase III trial. J Heart Lung Transplant 24 (2005) 185
11. Hussain T., Burch M., Fenton M., et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 115 (2007) 1798
12. Balk A., Linden M., Meeter K., et al. Is there a relationship between transplant coronary artery disease and the occurence of CMV infection. J Heart Lung Transplant 10 (1991) 188